Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Commissioner Von Eschenbach Makes Resignation Plans Official

This article was originally published in The Gray Sheet

Executive Summary

FDA Commissioner Andrew von Eschenbach will resign from the agency Jan. 20, which means the Obama administration needs to have an interim replacement ready to go on Inauguration Day

You may also be interested in...

GOP Lawmakers Signal FDA Won’t Escape Congressional Crosshairs In 2009

FDA remains in the crosshairs of congressional investigators, and given that Republicans are doing some of the gunning, the agency should expect continued barrages even after the change in administrations

FDA's Schwetz Is Acting Commissioner: Is RU-486 New Touchstone?

Acting Deputy Commissioner Bernard Schwetz, PhD, will oversee the agency following the resignation of FDA Commissioner Jane Henney, MD.

Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials

The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts